

DEEPER INSIGHTS INTO IMPACT OF ANTIOXIDANTS ON ANTICANCER DRUG-INDUCED LIPID PEROXIDATION: AYE AND NEY

¹Dr. Trilochan Satapathy (Corresponding Author)

²(Dr.) Bibhas Pandit (First Author)

³Ms. Pooja Tiwari (Co-author)

¹Dr. Trilochan Satapathy, Professor and Head,

Department of Pharmacology, Columbia Institute of Pharmacy, Near Vidhansabha, Tekari, Raipur, Chhattisgarh, India-493111.

²(Dr.) Bibhas Pandit, Assistant Professor,

Department of Pharmaceutical Chemistry, Columbia Institute of Pharmacy, Near Vidhansabha, Tekari, Raipur, Chhattisgarh, India-493111.

³Ms. Pooja Tiwari, Assistant Professor, SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Koni, Bilaspur, Chhattisgarh, India-495009

Abstract:

Anticancer agents are associated with a plethora of side effects. Individual agent, within each category, has its own set of adverse reactions based on specific mechanism which in turn cause patient in compliance and deterioration of the quality of life. Among the different adverse reactions, the major one is drugs targeting the DNA, where there is an excessive production of reactive oxygen species (ROS) and subsequent buildup of oxidative stress. Several dietary supplements have been proposed by different researchers to curb these undesired side effects, amongst which antioxidants have gained increasing popularity as an adjuvant in chemotherapy. Cancer patients received chemotherapy may develop various kidney lesions that impair their life style, immediate survival as well as limit the adequate treatment of the underlying malignant process. The side effects associated with anticancer drugs are vomiting, stomatitis, diarrhea, desquamation of skin, alopecia, bone marrow depression, hepatotoxicity, ototoxicity, nephrotoxicity, cardiotoxicity and many more. There are many mechanisms developed to describe the consequences of drug toxicity. One of them is lipid peroxidation. Peroxidation of lipid results in progressive deterioration of membrane structure and loss of proper functioning of cell in the presence of oxygen free radicals. All drugs are required to cross the omnipresent membrane to produce desired pharmacological action. The drugs may cause perceptible or detectable changes in the lipid profile while crossing the membrane phospholipids. So, drugs are the potential candidates to initiate lipid peroxidation. As lipid peroxidation is one of the reasons of drug toxicity, this article is a review of anticancer drugs that have the capacity to induce lipid peroxidation as a basis of adverse effects and significances of antioxidant as a suppressor of anticancer drug-induced lipid peroxidation.

Keywords: Lipid peroxidation, antioxidants, anticancer drugs, adverse effects, drug toxicity

Introduction

Biological membranes are very prone to oxidative damage. Peroxidation of lipid results in progressive deterioration of membrane structure and loss of proper functioning of the cell. In general, oxidative degradation of cholesterol and phospholipids containing polyunsaturated fatty acids (PUFA) are called lipid peroxidation [1]. The damage of both PUFA and cholesterol are facilitated by enzymatic and non-enzymatic lipid peroxidation pathways shown in **figure 1**. Non-enzymatic oxidation of lipids can be of free radical-mediated or free radical independent [2]. Peroxidation of PUFA results from the interactions of free-radicals with cholesterol and phospholipids takes place through five basic elementary reactions. These are (i) hydrogen atom transfer from PUFA to the chain carrying peroxy radicals, (ii) reaction of the lipid radical with molecular oxygen, (iii) fragmentation, (iv) rearrangement and (v) Cyclization of the peroxy radical [3-4]. Lipoxygenases (LOX), cyclooxygenases (COX) and cytochrome P-450 (CYP) participate in the enzymatic degradation of arachidonic acid (AA), a phospholipid to form hydroperoxyeicosatetraenoic acids (HPETEs), lipoxins, leukotrienes, epoxyeicosatrienoic acids, leukotoxins, and thromboxane as oxidative products of lipid. Non-enzymatic oxidation is known as auto-oxidation of lipids. Auto-oxidation is a spontaneous free radical chain reaction in which oxygen and transition metal produce superoxide or hydroxide free radicals by hemolysis of endogenous hydroperoxides [5-7].

Cells, tissues, and organs injuries are the magnitudes of oxidative damage results from lipid peroxidation. High levels of reactive oxygen species (ROS) can cause direct damage to lipids, proteins, or DNA [8-9]. Lipid peroxidation leads to many pathological conditions and toxic manifestations. They include liver injury, atherosclerosis, intermittent claudication, neuronal ceroidlipofuscinosis, structural derangement of the lipid bi-layer, increased the permeability of cytosolic constituents, inactivation of intrinsic enzymes and much more [1, 10-11].

To prevent the consequences of lipid peroxidation, cells produce manganese superoxide dismutase (Mn-SOD) and zinc or copper superoxide dismutase (Zn/Cu-SOD) from liver and stored them into mitochondria and cytosol respectively. They convert superoxide to hydrogen peroxide when required by the cells. Hydrogen peroxide is then catalyzed by catalase enzyme into water and oxygen. Glutathione and nitric oxide also help to prevent the damage from ROS. Reduced glutathione and nitric oxide are the two most important antioxidants produced by the body to protect cells from oxidative damage. Reduced glutathione (GSH) is a linear tripeptide of L-glutamine, L-cysteine, and glycine found in liver contain a sulfhydryl (SH) group on the cysteinyl portion, which accounts for its strong electron-donating character. It acts by quenching reactive hydroxyl free radicals, other oxygen-centered free radicals, and radical centers on DNA. It is a primary protectant of skin; lens, cornea, and retina against radiation damage [12-16].

Nitric oxide is secreted from the vascular endothelial cell in blood. Lipid oxidation can also be initiated by ferryl hemoglobin, formed from the interaction of hemoglobin with peroxides. Nitric oxide has been shown to reduce the ferrylheme and so prevent lipid oxidation by this mechanism [17]. According to the free radical hypothesis in term of oxidative stress, the damage is caused by a shift in the balance between the pro-oxidative and anti-oxidative processes

in the direction of the pro-oxidative state. This increases the chances of cancer, angiogenesis, carcinogen metabolism, and metastasis [10, 18].

Anticancer drugs are used to kill the uncontrolled proliferating tumor cells of our body. Due to narrow therapeutic index, high dose of these drugs is often used to achieve the desired therapeutic response. The normal tissues such as rapidly proliferating normal cells of bone marrow, gastrointestinal tract and hair follicles are also affected along with abnormal cells during the chemotherapy. Adverse effects are one of the leading causes of failure of most antineoplastic agents. Some common adverse effects associated with anticancer drugs are drowsiness, lethargy, tiredness, fatigue, insomnia, dizziness, unsteadiness, vertigo, imbalance, ataxia, diplopia, tremor, cognitive impairment, irritability, aggressive behavior, depression; gastrointestinal symptoms etc [19-21]. There are many mechanisms developed to describe the adverse effects produced by anticancer drugs. Lipid peroxidation is one of them. As most of the drugs have to pass through the omnipresent membrane and phospholipid is one of the components of the cell membrane, are very liable to induce lipid peroxidation [22].

Antioxidants are the substances that protect cells from the injury caused by free radicals. They are capable of slowing or preventing the oxidation of other molecules. Oxidation is a chemical reaction that can produce free radicals, which start chain reactions that damage cells. Antioxidants terminate these chain reactions by eliminating free radical intermediates and inhibit other oxidation reactions by being oxidized themselves. The free radical injury may lead to cancer also. Antioxidants may play a very important role in the management of cancer chemotherapy [23]. Examples of antioxidants include beta-carotene, lycopene, phenolic acid, flavonoids, vitamins C, E, A, and other naturally occurring substances [24-30].

The central theme of this review article can be stated in few words. The development of a new drug requires a huge investment of money and time. Whereas their many drugs available in the market whose applications are limited as they show moderate to severe toxicity. If the toxicity is optimized then the therapeutic efficacy of those drugs could be improved. We know that therapeutic index of a drug depends on Toxic Dose (TD_{50}) / Effective Dose (ED_{50}) values. If toxic dose increased then the therapeutic index can be improved which is shown in **figure 2**.

It means that the drug will show toxic effects in a higher dose. But how the toxicity can be improved? As lipid peroxidation is one of the causes of adverse effects shown by the anticancer drugs [23, 31-32], the use of antioxidants co-therapy during the cancer chemotherapy could be a useful tool to optimize or reduce the chances of adverse effects produced by them.

Mechanism and toxicological manifestations of anticancer drugs as a consequence of lipid peroxidation

The basic mechanism through which most of the anticancer drugs acts is summarized in **figure 3**. As antineoplastic agents act by participating in cell division, they must cross the cell membrane to interact with DNA and their bases. It is believed that most of the anticancer drugs kill cells, primarily through a programmed, energy-dependent process

called apoptosis, rather than through cell necrosis. Different classes of anticancer drugs show the different mechanism of cell apoptosis. Antimetabolites inhibit DNA synthesis whereas alkylating agents and antibiotics damage or disrupt DNA by interfering topoisomerase activity or alter ribonucleic acid (RNA) structure. Steroids interfere with transcription, several plant alkaloids interrupt mitosis, asparaginase destroys essential amino acids needed for translation, and other drugs act through important growth factor signal transduction pathways. Many clinically used antineoplastic agents undergo either chemical or enzymatic modification to exhibit cytotoxicity [20, 33]. While producing desired therapeutic effects they induce nephrotoxicity, ototoxicity, neurotoxicity, hepatotoxicity, cardiotoxicity as major adverse effects.

Nephrotoxicity

Acute renal toxicity is one of the most observed side effects exposed by anticancer drugs like cisplatin and ifosfamide [34-38]. Ifosfamide showed nephrotoxicity in children endured cancer chemotherapy. It reduces glutathione concentration and inhibits glutathione-S-transferase activity by inducing lipid peroxidation, leads to typical morphological damages in renal tubules and glomeruli [39-40]. The clinical application of cisplatin is limited due to its capability to produce nephrotoxicity. Nephrotoxicity showed by cisplatin is a magnitude of lipid peroxidation in kidney cortex [41-43].

Ototoxicity

Carboplatin is a second generation platinum-containing anticancer drug. It is used in the treatments of small-cell lung cancer, ovarian cancer, and carcinoma of the head. Carboplatin persuaded high-frequency hearing loss which is related to a depleted concentration of GSH, inhibition of antioxidant enzyme activities, depletion of enzyme Mn-SOD activities and enhanced lipid peroxidation in the cochleae [44-45]. Oxaliplatin, another drug of this category, widely used in the treatment of colorectal cancer show severe side effects such as neuropathy, ototoxicity, gastrointestinal toxicity, and hematological toxicity. Studied showed that the toxicity associated with oxaliplatin was the results of induced lipid peroxidation in cochleae and microsomal cells [46].

Hepatotoxicity

Topotecan, a semi-synthetic derivative of camptothecin, exhibited hepatotoxicity as a side effect by increasing the concentration of peroxide radicals and decreased in antioxidant enzyme activities in liver cells [47]. Flutamide, an androgen produced hepatotoxicity by decreasing GSH content in isolated rat hepatocytes [48]. Phototoxicity of flutamide both in aerobic or anaerobic conditions was mediated by photosensitization and concomitant singlet oxygen production [49-50]. Flutamide prompt hepatotoxicity by increasing cellular oxidative stress [51].

Cardiotoxicity

Adriamycin, epirubicin, and daunorubicin promoted the lipid peroxidation in liver and heart microsomes by reducing the activity of cytochrome P-450 reductase. The major side effect related to this drug is cardiotoxicity [52-53]. The

anthracyclines, such as doxorubicin and epirubicin, are potent cytotoxic drugs but clinical use of these drugs was often limited due to cardiotoxic side effects. Other cytotoxic drugs that were reported cardiotoxicity include 5-fluorouracil, capecitabine, mitoxantrone, cisplatin, the taxoids paclitaxel, and docetaxel. Lipid peroxidation was found to be the causative factor of this toxicity. The possible susceptibility of the cardiac cells to the oxidative stress would be due to relatively low levels of antioxidant enzymes in the heart [54-58]. Doxorubicin showed cytotoxic effect through the generation of superoxide radicals in the human breast tumor cell line MDA-MB-231. Experiment on microsomal cells confirmed cardiotoxic effect due to the increased concentration of lipid hydroperoxide in cardiac muscles [59-60].

Miscellaneous

The clinical uses of bleomycin as an antineoplastic drug are restricted due to its ability to produce pulmonary fibrosis [61]. The ability of bleomycin to induce lipid peroxidation in the liver and lung microsomes reported recently. It abridged microsomal GSH concentration [62-64]. Letrozole caused polycystic ovary (PCO) in the rat. A significant increase in cellular lipid peroxidation (LPO) and peroxynitrite (ONOO.) radical after the administration of letrozole revealed its capacity to induce lipid peroxidation. Also, it decreased the ovarian concentration of SOD, catalase (CAT) and glutathione peroxidase (GPx) during the therapy [65]. Mechlorethamine, chlorambucil, cyclophosphamide, carmustine, and lomustine are nitrogen mustered readily induced cytotoxicity in isolated rat hepatocytes. Depletion in the concentration of GSH, Nitric oxide (NO) and generation of 4-HNE in blood confirmed lipid peroxidation induction capacity of the drugs [66-71]. The in-vivo experimental study was carried out to establish the mechanism of the adverse effect produced by paclitaxel in Wistar rat. The study revealed that paclitaxel-induced lipid peroxidation as a consequence of toxic side effect [72]. Romidepsin is used to treat leukemia. It stimulated hydrogen peroxide activity to lift apoptosis of normal cells as a toxic side effect [73].

Effects of antioxidant on cancer and anticancer drug-induced lipid peroxidation

Apoptosis and cancer are opposite phenomena, but ROS have been widely reported to play a key role in both. There is evidence that apoptosis can be induced by ROS and induction of intracellular production of ROS is inhibited by the addition of antioxidants [74]. Although the mechanism involved is still controversial, but the redox status and hydrogen peroxide both have been proposed as critical factors. In addition, induction of carcinogenesis has been clearly linked to oxidative DNA damage. The oxidative product of DNA, 8-oxo-2'-deoxyguanosine, was reported to be highly mutagenic in nature. ROS are thought to contribute to carcinogenesis through interference with signal cascade systems, including the nuclear transcription factor kappaB (NF- κ B), activated protein-1 (AP-1), phospholipase A2, mitogen-activated protein kinases (MAPKs) and c-Jun kinase. Cells react rapidly to redox imbalance [75-77].

Vinorelbine, vincristine, vinblastine, and vindesine are vinca alkaloids used to control the growth of proliferative malignant cancer cells. These class of drugs produced ROS which leads to DNA damage and mitochondrial dysfunction of normal cells along with adenocarcinoma cells [78]. Lenalidomide, an analog of thalidomide is a potent inhibitor of

tumor necrosis factor alpha (TNF- α). It initiates lipid peroxidation to induce cellular apoptosis [79]. NF- κ B is a potential therapeutic target for acute myelogenous leukemia (AML). Niclosamide showed antineoplastic activity by inhibiting the NF- κ B pathway in AML cells. It increased ROS levels to induce apoptosis [80].

From the above-mentioned evidence, it is well understood that the use of antioxidants not always beneficial during cancer chemotherapy as many anticancer drugs induce cell apoptosis by generating ROS. In the same time, it has been evidenced that anticancer drugs induced toxicity as a consequence of the formation of ROS. So, in those cases, an antioxidant can play a very key role to reduce/suppress the undesired effects induced by the drugs. The followings are some antioxidants displayed significant effects in lower the lipid peroxidation induced by anticancer drug as a consequences of adverse effects.

Ascorbic acid

Ascorbic acid or Vitamin C, a potent antioxidant, abundantly seen in nature showed a potential role to reduce cisplatin-induced lipid peroxidation in liver tissue homogenates [79]. Flutamide- and paclitaxel-induced lipid peroxidation can also be prevented by using ascorbic acid. It improved the therapeutic index of the drug by reducing toxicity, which may be mediated by free radical mechanisms [71, 81-83].

Caffeic acid

Effect of caffeic acid onto the interaction of DNA-anticancer drug was evaluated. Daunorubicin (DNR) was used for this study. The interaction efficiency between DNR and DNA was examined both in the presence and absence of caffeic acid. The study revealed that use of caffeic acid has both beneficial and complicated effects on DNR chemotherapy. [84]

Curcumin

Effects of curcumin on cisplatin- and oxaliplatin-induced oxidative stress in human embryonic kidney (HEK) 293 cells was carried out to explore the protective effects of antioxidants on anticancer drug-induced toxicity. The study revealed that curcumin improved the therapeutic index of both the drugs by reducing the oxidative stress during the treatment [85].

Epigallocatechingallate (EGCG) and theaflavin (TF)

Tea (*Camellia sinensis*) and its polyphenols like epigallocatechingallate (EGCG) and theaflavin (TF) exhibited potential anticancer activity in pre-clinical and clinical studies. The study found that the mechanisms through which tea and its polyphenols work were as anti-oxidant which induced detoxification system thereby inhibiting carcinogen metabolism and cancer initiation [86]

GSH and phenolic antioxidants

Cisplatin-induced nephrotoxicity was prevented by thiols (GSH and DTT) and phenolic antioxidants (DPPD and BHA) in renal cortical slices. The depletion of cellular thiols and the initiation of lipid peroxidation contributed to the cisplatin-induced nephrotoxicity [87]. Docetaxel is a semi-synthetic derivative of paclitaxel produces several toxic side effects due

to damage of normal cell-like hair follicles, bone marrow, and other germ cells. Docetaxel has the capability of inducing lipid oxidization and membrane damage in human hepatoma cells. The effect of antioxidant on docetaxel-induced lipid peroxidation was explored and found that using antioxidant can reduce the chances of the adverse effect produced by docetaxel [88].

Hesperetin

Cisplatin-induced ototoxicity was prevented by hesperetin, a flavonol obtained from plant origin. It increased antioxidant enzymes activity and reduced oxidant parameters in proliferating cochlear cells [89].

Myricetin and gossypol

Myricetin and gossypol are two plants derived antioxidants of quercetin family shown protective effects on bleomycin-induced DNA damage through the inhibition of peroxide free radicals [90]. The ability of bleomycin to enhance ion-catalyzed damage observed during the treatment can be protected by using any phenolic compounds concurrently [91]. An experimental study was carried out to determine the protective effects of quercetin on epirubicin-induced acute oxidative stress toxicity in rat liver cells and mitochondria. The results suggested quercetin, as a potent antioxidant to reduce the risk of epirubicin-induced acute toxicity [92].

Melatonin

Melatonin is a potent antioxidant. It worked by a) scavenging free radicals b) stimulating antioxidative enzymes, c) increasing the efficiency of mitochondrial oxidative phosphorylation and thereby lowered free radical generation [93-94]. It showed protective effects against Mitomycin C-Induced genotoxic damage in peripheral blood of rats [95-96]. Tamoxifen is extensively used in the treatment of breast cancer. It exposed increased microsomal membrane fluidity as an adverse effect. Melatonin reduced the risk of microsomal damage encountered by free radicals [97]. Melatonin was found to be effective in epirubicin-induced cardiotoxicity [98].

Morin

Morin, a member of flavonols, exert antioxidant potential and offer protection against the oxidative stress induced by hydrogen peroxide. Morin inhibited cyclophosphamide-, flutamide- and busulfan-induced lipid peroxidation both in goat liver and white New Zealand rabbit [99-103].

Polyphenols

Polyphenols possess excellent anti-oxidant, anti-inflammatory properties [104]. It also modulates cell signaling pathways leading to anti-cancer effects. Promising results of in-vitro and in-vivo experiments were observed while combinations of polyphenols and chemotherapeutic agents used. This opened up new avenues for the discovery of the ideal drug combinations for cancer chemotherapy [105]. It was also found that polyphenols played a very effective role

a negative result while administered along those drugs. This review will help the researcher and clinicians to understand the benefits as well as contradictory effects of antioxidants to reduce the toxicity produced by anticancer drugs and proper use of antioxidants in cancer chemotherapy.

References

- [1] Girotti AW. Mechanisms of lipid peroxidation. *J Free Radic Biol Med* 1985;1:87–95.
- [2] Shichiri M, Yoshida Y, Niki E. Unregulated Lipid Peroxidation in Neurological Dysfunction. *Omega-3 Fatty Acids in Brain and Neurological Health*, Elsevier; 2014, p. 31–55. doi:10.1016/B978-0-12-410527-0.00004-1.
- [3] Niki E, Yoshida Y, Saito Y, Noguchi N. Lipid peroxidation: mechanisms, inhibition, and biological effects. *Biochem Biophys Res Commun* 2005;338:668–76. doi:10.1016/j.bbrc.2005.08.072.
- [4] Porter NA, Caldwell SE, Mills KA. Mechanisms of free radical oxidation of unsaturated lipids. *Lipids* 1995;30:277–90.
- [5] Guichardant M, Chen P, Liu M, Calzada C, Colas R, Véricel E, et al. Functional lipidomics of oxidized products from polyunsaturated fatty acids. *Chemistry and Physics of Lipids* 2011;164:544–8. doi:10.1016/j.chemphyslip.2011.05.002.
- [6] Massey KA, Nicolaou A. Lipidomics of oxidized polyunsaturated fatty acids. *Free Radical Biology and Medicine* 2013;59:45–55. doi:10.1016/j.freeradbiomed.2012.08.565.
- [7] Repetto M, Semprine J, Boveris A. Lipid Peroxidation: Chemical Mechanism, Biological Implications and Analytical Determination. In: Catala A, editor. *Lipid Peroxidation*, InTech; 2012. doi:10.5772/45943.
- [8] Ayala A, Muñoz MF, Argüelles S. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. *Oxidative Medicine and Cellular Longevity* 2014;2014:1–31. doi:10.1155/2014/360438.
- [9] Marnett LJ. Oxy radicals, lipid peroxidation and DNA damage. *Toxicology* 2002;181–182:219–22.
- [10] Halliwell B. Biochemistry of oxidative stress. *Biochem Soc Trans* 2007;35:1147–50. doi:10.1042/BST0351147.
- [11] Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem* 1979;95:351–8.
- [12] Dröge W. Free radicals in the physiological control of cell function. *Physiol Rev* 2002;82:47–95. doi:10.1152/physrev.00018.2001.
- [13] Barrera G. Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy. *ISRN Oncology* 2012;2012:1–21. doi:10.5402/2012/137289.
- [14] Weisiger RA, Fridovich I. Superoxide dismutase. Organelle specificity. *J Biol Chem* 1973;248:3582–92.
- [15] Sargent JR, Tocher DR, Bell JG. The lipids. In: Halver J E, Hardy R W editor. *Fish Nutrition*, 3rd ed, San Diego, California: Elsevier 2002; pp. 181-257.

- [16] Puglia CD, Powell SR. Inhibition of cellular antioxidants: a possible mechanism of toxic cell injury. *Environ Health Perspect* 1984;57:307–11.
- [17] Hogg N, Kalyanaraman B. Nitric oxide and lipid peroxidation. *Biochimica et BiophysicaActa (BBA) - Bioenergetics* 1999;1411:378–84. doi:10.1016/S0005-2728(99)00027-4.
- [18] Rikans LE, Hornbrook KR. Lipid peroxidation, antioxidant protection and aging. *BiochimBiophysActa* 1997;1362:116–27.
- [19] Kirthi C, Afzal A, Reddy M, Aamir Ali S, Yerramilli A, Sharma S. A study on the adverse effects of anticancer drugs in an oncology center of a tertiary care hospital. *Int J Pharm Pharm Sci.* 2014;6(2):580-3.
- [20] Tripathy KD. Chemotherapy of Neoplastic Diseases In:*Essentials of Medical Pharmacology*. Jaypee Brothers Medical Publishers (P) Ltd. 6th Ed. St. Louls (USA), 2008; pp. 809-19.
- [21] Chopra D, Rehan H, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: A prospective observational survey. *Indian Journal of Medical and Paediatric Oncology* 2016;37:42. doi:10.4103/0971-5851.177015.
- [22] Sangeetha P, Das UN, Koratkar R, Suryaprabha P. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. *Free RadicBiol Med* 1990;8:15–9.
- [23] Fujita K, Shinpo K, Yamada K, Sato T, Niimi H, Shamoto M, et al. Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. *Cancer Res.* 1982;42(1):309-16.
- [24] Hamid AA, Aiyelaagbe OO, Usman LA, Ameen OM, Lawal A. Antioxidants : Its medicinal and pharmacological applications. *African J Pure ApplChem.* 2010;4(8):142-51.
- [25] Carocho M, Ferreira ICFR. A review on antioxidants, prooxidants, and related controversy: Natural and synthetic compounds, screening and analysis methodologies and future perspectives. *Food ChemToxicol.* 2013;51(1):15-25.
- [26] Niki E. Antioxidants in relation to lipid peroxidation. *ChemPhys Lipids.* 1987;44(2-4):227-53.
- [27] Williams RJ, Spencer JPE, Rice-Evans C. Flavonoids: Antioxidants or signaling molecules? *Free RadicBiol Med.* 2004;36(7):838–49.
- [28] Borek C. Dietary antioxidants and human cancer. *Integr Cancer Ther.* 2004;3(4):333-41.
- [29] Korkina LG, Luca CD, Kostyuk VA, Pastore S. Plant polyphenols and tumors: from mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments. *Curr Med Chem.* 2016;16(30):3943-65.
- [30] Nowak R, Olech M, Nowacka N. Plant Polyphenols as Chemopreventive Agents. *Polyphenols Hum Heal Dis.* 2013;2:1289-307.
- [31] Ravi R, Somani SM, Rybak LP. Mechanism of Cisplatin Ototoxicity: Antioxidant System. *Pharmacology & Toxicology* 1995;76:386–94. doi:10.1111/j.1600-0773.1995.tb00167.x.
- [32] Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. *FASEB J [Internet].* 1997;11(12):931-6.

- [33] Medical library. <http://doctorlib.info/pharmacology/illustrated/42.html> (Accessed February 16, 2016)
- [34] Lameire N. Nephrotoxicity of recent anti-cancer agents. *Clinical Kidney Journal* 2014;7:11–22. doi:10.1093/ckj/sft135.
- [35] Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. *Kidney Int.* 2008;73(9):994-1007. doi: 10.1038/sj.ki.5002786.
- [36] Bompart G. Cisplatin-induced changes in cytochrome P-450, lipid peroxidation, and drug-metabolizing enzyme activities in rat kidney cortex. *ToxicolLett.* 1989;48(2):193-9.
- [37] Bowlekar PB, Gadgoli HC. Amelioration of cisplatin induced nephrotoxicity by standardized methanolic extract of roots of *Boerhaavia diffusa*. *The Natural Products Journal.* 2014;4(3):217-23.
- [38] Herrera-Pérez Z, Gretz N, Dweep H. A comprehensive review on the genetic regulation of cisplatin-induced nephrotoxicity. *Curr Genomics.* 2016;17(3):279-93.
- [39] Chen N, Aleksa K, Woodland C, Rieder M, Koren G. N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. *Br J Pharmacol.* 2008;153(7):1364-72.
- [40] Fukasawa H, Furuya R, Yasuda H, Yamamoto T, Hishida A, Kitagawa M. Anti-cancer agent-induced nephrotoxicity. *Anticancer Agents Med Chem* 2014;14(7):921-7.
- [41] Field MJ, Bostrom TE, Seow F, Györy AZ, Cockayne DJ. Acute cisplatin nephrotoxicity in the rat. Evidence for impaired entry of sodium into proximal tubule cells. *Pflug Arch Eur J Phy.* 1989;414(6):647-50.
- [42] Barrera G. Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy. *ISRN Oncology* 2012;2012:1–21. doi:10.5402/2012/137289.
- [43] Vermeulen NPE, Baldew GS. The role of lipid peroxidation in the nephrotoxicity of cisplatin. *Biochemical Pharmacology* 1992;44:1193–9. doi:10.1016/0006-2952(92)90384-U.
- [44] Husain K, Whitworth C, Somani SM, Rybak LP. Carboplatin-induced oxidative stress in rat cochlea. *Hear Res.* 2001;159(1-2):14-22. doi: 10.1016/S0378-5955(01)00306-9.
- [45] Husain K, Scott RB, Whitworth C, Somani SM, Rybak LP. Dose response of carboplatin-induced hearing loss in rats: Antioxidant defense system. *Hear Res.* 2001;151(1-2):71-8.
- [46] Marmiroli P, Cavaletti G, Carozzi V, Riva B, Lim D, Genazzani AA. Calcium-related neurotoxicity of oxaliplatin: understanding the mechanisms to drive therapy. *Curr Med Chem.* 2015;22(32):3682-94.
- [47] Kisa U, Caglayan O, Kacmaz M. The effects of topotecan on lipid peroxidation and antioxidant enzyme levels in rabbit liver tissue. *Redox Rep.* 2005;10(2):79–82.
- [48] Vargas F, Rivas C, Méndez H, Fuentes A, Fraile G, Velásquez M. Photochemistry and phototoxicity studies of flutamide, a phototoxic anti-cancer drug. *J Photochem Photobiol B Biol.* 2000;58(2-3):108-14.
- [49] Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, et al. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. *J Pharm Exp Ther.* 1994;269(3):954-62.

- [50] Maruf AA, O'Brien P. Flutamide-Induced Cytotoxicity and Oxidative Stress in an In Vitro Rat Hepatocyte System. *Oxidative Medicine and Cellular Longevity* 2014;2014:1–9. doi:10.1155/2014/398285.
- [51] Teppner M, Boss F, Ernst B, Pahler A. Application of lipid peroxidation products as biomarkers for flutamide-induced oxidative stress in vitro. *Toxicol Lett.* 2015;238(3):53-9. doi: 10.1016/j.toxlet.2015.08.005.
- [52] Adao R, Rocha C M, Ribeiro DS, Ferreira PM, Moreir AF, Bras-Silva S. Cardiotoxicity of cancer chemotherapy—recent developments. *Frontiers in Drug Design & Discovery.* Bentham Science Publisher. 2016;7:36-83.
- [53] Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. *Science* 1977;197:165–7.
- [54] Schimmel KJM, Richel DJ, Brink RBA, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. *Cancer Treat Rev* 2004;30(2):181–91.
- [55] Eskandari MR, Moghaddam F, Shahraki J, Pourahmad J. A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drugcapecitabine. *Xenobiotica.* 2014;0(0):1–9. doi: 10.3109/00498254.2014.942809
- [56] Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention. *JNCI Journal of the National Cancer Institute* 2010;102:14–25. doi:10.1093/jnci/djp440.
- [57] Menna P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs. *Chem Res in Toxicol.*2008;21(5):978–89.
- [58] Novak RF, Kharasch ED. Mitoxantrone: propensity for free radical formation and lipid peroxidation implications for cardiotoxicity. *Invest New Drugs* 1985;3:95–9.
- [59] Germain E, Chajès V, Cognault S, Lhuillery C, Bognoux P. Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. *Int J Cancer* 1998;75:578–83.
- [60] Benckroun MN, Pourquier P, Schott B, Robert J. Doxorubicin-induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin. *Eur J Biochem* 1993;211:141–6.
- [61] Aso Y, Yoneda K, Kikkawa Y. Morphologic and biochemical study of pulmonary changes induced by bleomycin in mice. *Lab Invest [Internet].* 1976;35(6):558–68.
- [62] Wai-Ming T, Montgomery MR. Bleomycin toxicity: Alterations in oxidative metabolism in lung and liver microsomal fractions. *BiochemPharmacol.* 1980;29(24):3239-44.
- [63] Pereira CV, Moreira AC, Pereira SP, Machado NG, Carvalho FS, Sardao VA et al. Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety. *Curr Drug Safety.* 2016;4(1):34-54.
- [64] Giri SN, Chen ZL, Younker WR, Schiedt MJ. Effects of intratracheal administration of bleomycin on GSH-shuttle enzymes, catalase, lipid peroxidation, and collagen content in the lungs of hamsters. *Toxicol Appl Pharmacol* 1983;71:132–41.

- [65] Rezvanfar MA, Ahmadi A, Saadi HA, Baeeri M, Abdollahi M. Mechanistic links between oxidative/nitrosative stress and tumor necrosis factor alpha in letrozole-induced murine polycystic ovary: biochemical and pathological evidence for the beneficial effect of pioglitazone. *Hum Exp Toxicol*. 2012;31(9):887-97.
- [66] Khan S, Ramwani JJ, O'Brien PJ. Hepatocyte toxicity of mechlorethamine and other alkylating anticancer drugs. Role of lipid peroxidation. *Biochem Pharmacol*. 1992;43(9):1963-7.
- [67] Yaren H, Mollaoglu H, Kurt B, Korkmaz A, Oter S, Topal T, et al. Lung toxicity of nitrogen mustard may be mediated by nitric oxide and peroxy nitrite in rats. *Res Vet Sci*. 2007;83(1):116–22.
- [68] Zhenga R, Poa I, Mishina V, Blacka A, Heck DE, Laskina DL, et al. The generation of 4-hydroxynonenal, an electrophilic lipid peroxidation end product, in rabbit cornea organ cultures treated with UVB light and nitrogen mustard. 2013;272(2):245-55.
- [69] Korkmaz A, Yaren H, Topal T, Oter S. Molecular targets against mustard toxicity: implication of cell surface receptors, peroxy nitrite production, and PARP activation. *Arch Toxicol*. 2006;80(10):662-70.
- [70] Ray S, Pandit B, Das S, Chakraborty S. Cyclophosphamide-induced lipid peroxidation and changes in cholesterol content: Protective role of reduced glutathione. *Iran J Pharm Sci*. 2011;7(4):255-68.
- [71] Premkumar K, Pachiappan A, Abraham SK, Santhiya ST, Gopinath PM, Ramesh A. Effect of *Spirulina fusiformis* on cyclophosphamide and mitomycin-C induced genotoxicity and oxidative stress in mice. *Fitoterapia*. 2001;72(8):906-11.
- [72] Campos FC, Victorino VJ, Martins-Pinge MC, Cecchini AL, Panis C, Cecchini R. Systemic toxicity induced by paclitaxel in vivo is associated with the solvent cremophor EL through oxidative stress-driven mechanisms. *Food Chem Toxicol*. 2014;68:78–86.
- [73] Mizutani H, Hiraku Y, Tada-Oikawa S, Murata M, Ikemura K, Okuda M, et al. Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide. *Cancer Sci*. 2010;101(10):2214–19. doi:10.1111/j.1349-7006.2010.01645.x.
- [74] Moloney JN, Cotter TG. ROS signalling in the biology of cancer. *Seminars in Cell & Developmental Biology* 2017. doi:10.1016/j.semcdb.2017.05.023.
- [75] Matés JM, Sánchez-Jiménez FM. Role of Reactive Oxygen Species in Apoptosis: Implications for Cancer Therapy. *Int J Biochem Cell Biol*. 2000;32(2):157-70.
- [76] Liou MY, Storz P. Reactive oxygen species in cancer. *Free Radic Res*. 2010;44(5):1-31.
- [77] Milkovic L, Siems W, Siems R, Zarkovic N. Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. *Curr Pharm Des*. 2014;20:6529–42.
- [78] Chiu WH, Luo SJ, Chen CL, Cheng JH, Hsieh CY, Wang CY, et al. Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 down regulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells. *Biochem Pharmacol*. 2012;83(9):1159-71.
- [79] Zhu X, Jiang S, Hu N, Luo F, Dong H, Kang Y-M, et al. Tumour necrosis factor- α inhibition with lenalidomide alleviates tissue oxidative injury and apoptosis in ob/ob obese mice. *Clinical and Experimental Pharmacology and Physiology* 2014;41:489–501. doi:10.1111/1440-1681.12240.

- [80] Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. *Cancer Res.* 2010;70:2516–27. doi:10.1158/0008-5472.CAN-09-3950.
- [81] Ray S, Roy K, Sengupta C. Cisplatin-induced lipid peroxidation and its inhibition with ascorbic acid. *Indian J Pharm Sci.* 2006;68(2):199–204.
- [82] Ray S. Evaluation of Protective Role of Ascorbic Acid on Flutamide-Induced Lipid Peroxidation. *Int J PharmTech Res.* 2012;4(1):135–40.
- [83] Park JH, Davis KR, Lee G, Jung M, Jung Y, Park J, et al. Ascorbic acid alleviates toxicity of paclitaxel without interfering with the anticancer efficacy in mice. *Nutr Res.* 2012;32(11):873–83. doi:10.1016/j.nutres.2012.09.011.
- [84] Muti M, Muti M. Electrochemical monitoring of the interaction between anticancer drug and DNA in the presence of antioxidant. *Talanta* 2017. doi:10.1016/j.talanta.2017.08.089.
- [85] Waly MI, Al Moundhri MS, Ali BH. Effect of curcumin on cisplatin- and oxaliplatin-induced oxidative stress in human embryonic kidney (HEK) 293 cells. *Ren Fail.* 2011;33(5):518–23.
- [86] Sur S, Panda CK. Molecular aspects of cancer chemopreventive and therapeutic efficacies of tea and tea polyphenols. *Nutrition* 2017;43–44:8–15. doi:10.1016/j.nut.2017.06.006.
- [87] Kim YK, Jung JS, Sang Ho Lee SH, Kim YW. Effects of Antioxidants and Ca²⁺ in Cisplatin-induced cell injury in rabbit renal cortical slices. *Toxicol Appl Pharmacol* 1997;269(146):261–9.
- [88] Ray S, Mondal S, Ray SD, Roy PP. Role of antioxidants on docetaxel-induced in vitro lipid peroxidation using malondialdehyde as model marker: An experimental and in silico approach. *Med Chem Res.* 2014;23(10):4436–46.
- [89] Kara M, Türkön H, Karaca T, Güçlü O, Uysal S, Türkyilmaz M, et al. Evaluation of the protective effects of hesperetin against cisplatin-induced ototoxicity in a rat animal model. *Int J Pediatr Otorhinolaryngol.* 2016;85:12–8.
- [90] Laughton MJ, Halliwell B, Evans PJ, Robin J, Houlst S. Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin. Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA. *Biochem Pharmacol.* 1989;38(17):2859–65.
- [91] Gutteridge JMC, Xiao-Chang F. Enhancement of bleomycin—iron free radical damage to DNA by antioxidants and their inhibition of lipid peroxidation. *FEBS letters.* 1981;123(1):71-4.
- [92] Kebieche M, Lakroun Z, Lahouel M, Bouayed J, Meraihi Z, Soulimani R. Evaluation of epirubicin-induced acute oxidative stress toxicity in rat liver cells and mitochondria, and the prevention of toxicity through quercetin administration. *Exp Toxicol Pathol.* 2009;61(2):161–7.
- [93] Reiter RJ, Tan DX, Mayo JC, Sainz RM, Leon J, Czarnecki Z. Melatonin as an antioxidant: Biochemical mechanisms and pathophysiological implications in humans. *Acta Biochimica Polonica.* 2003;50(4):1129–46.
- [94] Ruiz-Rabelo J, Vázquez R, Arjona A, Perea D, Montilla P, Túnez I, et al. Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer. *Pancreas* 2011;40:410–4. doi:10.1097/MPA.0b013e318201ca4f.

- [95] Ortega-Gutiérrez S, López-Vicente M, Lostalé F, Fuentes-Broto L, Martínez-Ballarín E, García JJ. Protective Effect of Melatonin Against Mitomycin C-Induced Genotoxic Damage in Peripheral Blood of Rats. *Journal of Biomedicine and Biotechnology* 2009;2009:1–6. doi:10.1155/2009/791432.
- [96] Siddique YH, Ara G, Beg T, Gupta J, Afzal M. Assessment of cell viability , lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and curcumin in cultured human blood lymphocytes. *Exp Toxicol Pathol.* 2010;62(5):503–8. doi:10.1016/j.etp.2009.06.010
- [97] Reiter RJ, Ortiz GG, Oh CS, Tang L, Yu BP, Escames G. Membrane biology melatonin enhances tamoxifen's ability to prevent the reduction in microsomal membrane fluidity induced by lipid peroxidation. *J Membrane Biol.* 1998;65:59–65.
- [98] Guven A, Yavuz O, Cam M, Ercan F, Bukan N, Comunoglu C. Melatonin protects against epirubicin-induced cardiotoxicity. *Acta Histochem.* 2007;109(1):52–60.
- [99] Ray S. Evaluation of Protective role of Morin on Busulfan-induced lipid Peroxidation. *Int J PharmTech Res.* 2011;3(4):2222-7.
- [100] Ray S, Chowdhury P, Pandit B, Ray SD, Das S. Exploring the antiperoxidative potential of morin on cyclophosphamide and flutamide-induced lipid peroxidation and changes in cholesterol profile in rabbit model. *Acta Pol Pharm - Drug Res.* 2010;67(1):35–44.
- [101] Pietta PG. Flavonoids as antioxidants. *J Nat Prod.* 2000;63(7):1035–42.
- [102] Rappeneau S, Baeza-Squiban A, Jeulin C, Marano F. Protection from cytotoxic effects induced by the nitrogen mustard mechlorethamine on human bronchial epithelial cells in vitro. *Toxicol Sci* 2000;54:212–21.
- [103] Li HW, Zou T Bin, Jia Q, Xia EQ, Cao WJ, Liu W, et al. Anticancer effects of morin-7-sulphate sodium, a flavonoid derivative, in mouse melanoma cells. *Biomed Pharmacother.* 2016;84:909–16. doi:10.1016/j.biopha.2016.10.001.
- [104] Carrasco-Pozo C. Protection by Polyphenols Against Mitochondrial Damage and Cytotoxicity. *Polyphenols in Human Health and Disease*, Elsevier; 2014, p. 731–46. doi:10.1016/B978-0-12-398456-2.00057-8.
- [105] Mohan A, Narayanan S, Sethuraman S, Uma, Krishnan UM. Combinations of plant polyphenols & anti-cancer molecules: a novel treatment strategy for cancer chemotherapy. *Anticancer Agents Med Chem.* 2013;13(2):281-95.
- [106] Stepanic V, Gasparovic AC, Troselj KG, Amic D, Zarkovic N. Selected attributes of polyphenols in targeting oxidative stress in cancer. *Curr Topic Med Chem.* 2015;15(5): 496-509.
- [107] Matsui-Yuasa I, Kojima-Yuasa A. Effect of Green Tea Extract and Tea Polyphenols Against Antibiotic-, Anti-Cancer Drug- and Immunosuppressant Agent-Induced Nephrotoxicity. *Tea in Health and Disease Prevention*, Elsevier; 2013, p. 1299–307. doi:10.1016/B978-0-12-384937-3.00109-9.
- [108] Psotova J, Ulrichova J. Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. 2002;67:63-7.
- [109] Quiles JL, Huertas JR, Battino M, Mataix J, Ramírez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. *Toxicology.* 2002;180(1):79–95.

- [110] Puglia CD, Powell SR. Inhibition of cellular antioxidants: a possible mechanism of toxic cell injury. *Environ Health Perspect.* 1984;57(7):307-11.
- [111] Manna A, Chattopadhyay S, Chatterjee M. Plant-derived pro-oxidants as potential anticancer therapeutics In: . *Studies in Natural Product Chemistry.* Elsevier Science B. V: Amsterdam, 2016; Vol. 50, pp 81-129.
- [112] Khan HY, Zubair H, Ullah MF, Ahmad A, Hadi SM. A prooxidant mechanism for the anticancer and chemopreventive properties of plant polyphenols. *Curr Drug Targets.* 2012;13:1738–49.
- [113] Russo GL, Tedesco I, Spagnuolo C, Russo M. Antioxidant polyphenols in cancer treatment: Friend, foe or foil? *Seminars in Cancer Biology* 2017. doi:10.1016/j.semcan.2017.05.005.
- [114] Andueza S, Manzocco L, Paz de Peña M, Cid C, Nicoli C. Caffeic acid decomposition products: Antioxidants or pro-oxidants? *Food Res Int.* 2009;42(1):51-5. doi:10.1016/j.foodres.2008.08.006.
- [115] Halliwell B. Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies? *Arch Biochem Biophys.* 2008;476(2):107-12.
- [116] Yen GC, Duh P Der, Tsai HL. Antioxidant and pro-oxidant properties of ascorbic acid and gallic acid. *Food Chem.* 2002;79(3):307–13.
- [117] Putchala MC, Ramani P, Sherlin HJ, Premkumar P, Natesan A. Ascorbic acid and its pro-oxidant activity as a therapy for tumours of oral cavity-A systematic review. *Arch Oral Biol.* 2013;58(6):563–74. doi:10.1016/j.archoralbio.2013.01.016.





Figure 1: Lipid peroxidation pathways of membrane phospholipid



Foot Note: PLA (Phospholipase-A), COX (Cyclooxygenase), LOX (Lipoxygenase), CYP (Cytochrome P₄₅₀), .OH (Hydroxyl free radical), H₂O₂ (Hydrogen peroxide), O₂^{•-} (Superoxide free radical).

Figure 2: Relationship of Therapeutic index with Toxic dose₅₀ and Effective dose₅₀. TI increases when TD₅₀ value of a drug increases.




Figure 3: Mechanism of action of anticancer drugs.

